APPLICATION OF ANALYTICAL QUALITY BY DESIGN IN CHROMATOGRAPHIC METHOD DEVELOPMENT: A PHARMACEUTICAL PERSPECTIVE

Analytical method development plays a critical role in ensuring the quality, safety, and efficacy of pharmaceutical products. Conventional chromatographic method development often relies on trial- and-error experimentation, which may lead to variability and limited robustness. Analytical Quality by Design (AQbD) has emerged as a systematic, science- and risk-based framework that enhances method understanding and reliability throughout the analytical lifecycle. The AQbD approach begins with defining the Analytical Target Profile (ATP), followed by identification of Critical Quality Attributes (CQAs) and Critical Method Parameters (CMPs) using risk assessment tools. Statistical techniques such as Design of Experiments (DoE) enable optimization of chromatographic conditions and establishment of the Method Operable Design Region (MODR), ensuring consistent performance within defined boundaries. Integration of lifecycle management, control strategy, and continuous monitoring further strengthens method robustness and regulatory flexibility. This review provides a comprehensive pharmaceutical perspective on the application of AQbD in chromatographic method development, highlighting key tools, regulatory expectations, advantages over traditional approaches, and current implementation challenges. Adoption of AQbD facilitates development of reliable, cost-effective, and regulatory-compliant chromatographic methods, ultimately supporting consistent pharmaceutical product quality.